By Daniella Parra
March Biosciences has closed an oversubscribed $28.4 million Series A financing, led by Mission BioCapital and 4BIO Capital to advance its innovative autologous chimeric antigen receptor T-cell (CAR-T) therapy and more, it said.
The therapy is aimed at treating T-cell lymphoma, a condition with few treatment options.
Additionally, the company partnered with Volnay Therapeutics to enhance their manufacturing process and expand their treatment pipeline with several investors joining the company’s board of directors, they said.
“This oversubscribed financing enables us to advance our first-in-class CAR-T therapy, MB-105, into a Phase 2 trial for T-cell lymphoma – an indication with an exceptionally poor prognosis and few treatment options,” said Sarah Hein, Co-Founder and Chief Executive Officer of March Biosciences. “With the support and confidence of our investors, we are not only advancing our lead program but also expanding our pipeline, underscoring our commitment to delivering best-in-class therapies to patients that can change the treatment paradigm for these challenging cancers.”
Contact:
Editor@executives-edge.com